Healthcare / Medical Devices / Signal Release

Press Release

Pheonix Research Releases 2026–2033 E-Prescribing Forecast: USD 4.34 Billion by 2033 as 11.5 Network Events Ride on Every Prescription

· Healthcare

FOR IMMEDIATE RELEASE

18 November 2026 — Pheonix Research today publishes Global E-Prescribing Market Report, Size, Share and Forecast 2026–2033, which sizes the global e-prescribing market at USD 1,940.0 million in 2025 and forecasts USD 4,340.0 million by 2033 — a 10.59 per cent compound annual growth rate and USD 2,400.0 million of new value.

The report’s finding is that transmission has become a utility and the growth has moved elsewhere. Electronic prescription volume rises only from 4,500 million to 6,120 million over the period, 3.92 per cent a year, so the 10.59 per cent value rate is carried by what now travels alongside each prescription rather than by more prescriptions. Value per e-prescription rises from USD 0.43 to USD 0.71.

“E-prescribing stopped being a transmission business when transmission became free,” said the Pheonix Research healthcare devices team. “The tenth and eleventh events on a prescription are billed. The first one is not.”

Key findings

  • There is almost no adoption left to sell. 84.4 per cent of US e-prescribers are enabled for controlled substances, 98.3 per cent of pharmacies can receive them, and in England 1.16 billion of the 1.19 billion items dispensed in 2025/26 moved electronically.
  • The event count per prescription is the market. The Surescripts network exchanged 27.2 billion transactions against 2.6 billion prescriptions in 2024 — 10.46 events per prescription. In 2025 transactions grew 12.3 per cent to 30.5 billion while prescription volume grew at roughly a fifth of that rate, taking the ratio to about 11.5 events per prescription, a 10.04 per cent rise in one year.
  • Value has moved to the decision layers. Benefit and price intelligence plus prior authorisation carry 39.2 per cent of 2025 value and 55.1 per cent by 2033, while transmission and prescriber-side software fall from 48.5 per cent to 34.1 per cent. Prior authorisation is the fastest layer at 18.53 per cent, from USD 290 million to USD 1,130 million.
  • Two regulatory dates set the shape of the curve. The CMS Interoperability and Prior Authorization final rule requires affected payers to implement HL7 FHIR Prior Authorization APIs, with compliance generally from 1 January 2027. The European Health Data Space Regulation, in force since 26 March 2025, applies cross-border ePrescription and eDispensation exchange from March 2029. European value share rises from 21 per cent to 26 per cent as North America’s falls from 62 to 55.
  • Two jurisdictions are four fifths of the world. The United States, at approximately 2,650 million e-prescriptions, and England, at 1,160 million on an official statistic, account for 84.7 per cent of global electronic prescription volume.
  • Only 2.7 per cent of the market reconciles to a filing. Surescripts is privately held; Epic, athenahealth and MEDITECH are private or privately owned; Oracle’s health disclosure does not isolate prescribing. The model is built from disclosed transaction counts rather than reported revenue, and every allocation is labelled.

“A market can be enormous, standardised and almost entirely invisible in the accounts of the companies that run it,” the team said. “That is where this one is. The sizing has to be reconstructed from volume, because revenue does not exist in public to be counted.”

Two downside cases, and they converge

If value per e-prescription grows at 4 per cent rather than 6.42 per cent — because platform vendors bundle the decision layers rather than pricing them — 2033 lands at USD 3,611.3 million instead of USD 4,340.0 million. If prior authorisation grows at 12 per cent rather than 18.53 per cent, 2033 lands at USD 3,622.0 million. Both downside paths arrive near USD 3.6 billion, and the report states both on the page.

Report details

  • Title: Global E-Prescribing Market Report, Size, Share and Forecast 2026–2033: The Prescription Is Now the Smallest Part of E-Prescribing
  • Base year and horizon: 2025 base, forecast to 2033.
  • Coverage: global, by value layer — transmission and network, prescriber-side software, benefit and price intelligence, prior authorisation, and dispensing and reconciliation — across retail pharmacy, hospital, and long-term and specialty care.
  • Chapters: competitive landscape; value chain and cost structure; investment activity; technology and innovation; market risk and scenarios; regulatory landscape.
  • Methodology: a 70/30 split of secondary and primary evidence, with primary work concentrated on price bands, the specification chain, switching costs and the payback arithmetic prescribers apply to authorisation automation. No market-research competitor data is cited.
  • Available at: pheonixresearch.com/healthcare/medical-devices/market-report/global-e-prescribing-market/

About Pheonix Research

Pheonix Research is a market intelligence platform that queries a live graph of more than 500 market nodes to surface leading signals and translate them into role-specific decisions. It publishes market reports across industrial, healthcare and technology sectors, built from disclosed primary sources, a structured primary research programme, and a documented model in which every estimated figure is identified as an estimate.

Media contact

Pheonix Research
Research & Intelligence: [email protected]
Sales & Engagements: [email protected]
Website: www.pheonixresearch.com

— Ends —